Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
Xiekui Cui *Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA.
Han Yang *Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-9150-8146
Charles CaiInstitute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA.
Cooper BeamanInstitute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-0933-5504
Xiaoyu YangInstitute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA.
Hongjiang LiuInstitute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-6600-642X
Xingjie RenInstitute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-2348-4162
Zachary AmadorInstitute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-7151-9323
Ian R JonesInstitute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA.ORCID 0009-0001-2227-9618
Kathleen C KeoughPharmaceutical Sciences and Pharmacogenomics Graduate Program, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-7481-0511
Meng ZhangHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-1042-6294
Tyler FairEli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, Univeristy of California, San Francisco, San Francisco, CA, USA.
Armen AbnousiDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0000-0003-1822-0928
Shreya MishraDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Zhen YeInstitute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA.
Ming HuDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0000-0003-0987-2916
Alex A PollenEli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, Univeristy of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-3263-8634
Katherine S PollardInstitute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA.
Yin ShenInstitute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA. Yin.Shen@ucsf.edu.ORCID 0000-0001-9901-5613
Funding
Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VAISSE, CHRISTIAN · 2003 to 2019
$21.8M
High throughput CRISPR-mediated functional validation of regulatory elementsUM1HG009402 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI REN, BING, SHEN, YIN · 2017 to 2021
$8.4M
Charting the 3D epigenome in human brain development and diseasesU01DA052713 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRIEGSTEIN, ARNOLD, SHEN, YIN · 2020 to 2024
$3.4M
Massively parallel dissection of psychiatric regulatory networksR01MH109907 · NIMH · J. DAVID GLADSTONE INSTITUTES · PI AHITUV, NADAV, POLLARD, KATHERINE S. · 2016 to 2020
$3.4M
Massively parallel characterization of psychiatric disease associated regulatory elements in defined cell typesU01MH116438 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHITUV, NADAV, POLLARD, KATHERINE S. · 2018 to 2021
$2.7M
Establishing A Stem Cell Biology Platform for Decoding the Genetic Basis of Human Brain SpecializationsDP2MH122400 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI POLLEN, ALEXANDER A · 2019 to 2019
$2.4M
BD FACSAria Fusion Cell SorterS10OD021822 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEE, MICHAEL R. · 2016 to 2016
$573k
Dissecting functional roles of MeCP2 condensates in neurons with chemogenetic toolsR21DA056293 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHEN, YIN · 2022 to 2023
$444k
Development of massively parallel reporter assays that use cognate promotersR21HG010065 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHITUV, NADAV, SHEN, YIN · 2018 to 2019
Human accelerated regions (HARs) are conserved genomic loci that have experienced rapid nucleotide substitutions following the divergence from chimpanzees
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Comparative characterization of human accelerated regions in neurons. · full record | OpenQuestion